[go: up one dir, main page]

GB201018289D0 - Treatment of respiratory disorders - Google Patents

Treatment of respiratory disorders

Info

Publication number
GB201018289D0
GB201018289D0 GBGB1018289.7A GB201018289A GB201018289D0 GB 201018289 D0 GB201018289 D0 GB 201018289D0 GB 201018289 A GB201018289 A GB 201018289A GB 201018289 D0 GB201018289 D0 GB 201018289D0
Authority
GB
United Kingdom
Prior art keywords
adjuvant
lipid
ibuprofen
treatment
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1018289.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocopea Ltd
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Priority to GBGB1018289.7A priority Critical patent/GB201018289D0/en
Publication of GB201018289D0 publication Critical patent/GB201018289D0/en
Priority to GB1113728.8A priority patent/GB2487808A/en
Priority to PCT/GB2011/052115 priority patent/WO2012056251A1/en
Priority to EP11784752.5A priority patent/EP2632431A1/en
Priority to CA2816564A priority patent/CA2816564A1/en
Priority to AU2011322255A priority patent/AU2011322255A1/en
Priority to JP2013535515A priority patent/JP2013544802A/en
Priority to BR112013010441A priority patent/BR112013010441A2/en
Priority to CN2011800637601A priority patent/CN103282021A/en
Priority to SG2013033014A priority patent/SG189551A1/en
Priority to MX2013004817A priority patent/MX2013004817A/en
Priority to RU2013124514/15A priority patent/RU2013124514A/en
Priority to US13/365,824 priority patent/US8895536B2/en
Priority to US13/365,828 priority patent/US8895537B2/en
Priority to US14/155,167 priority patent/US10695432B2/en
Priority to US14/155,042 priority patent/US9271950B2/en
Priority to US14/155,080 priority patent/US9265742B2/en
Priority to US14/155,147 priority patent/US10695431B2/en
Priority to US14/155,108 priority patent/US9308213B2/en
Priority to US14/520,141 priority patent/US9326958B2/en
Priority to US14/520,150 priority patent/US9381180B2/en
Priority to US14/520,159 priority patent/US9427422B2/en
Priority to US14/821,687 priority patent/US9744132B2/en
Priority to US14/975,599 priority patent/US9504664B2/en
Priority to US14/975,608 priority patent/US9737500B2/en
Priority to US15/043,327 priority patent/US9750810B2/en
Priority to US15/061,661 priority patent/US9775820B2/en
Priority to US15/169,619 priority patent/US10004704B2/en
Priority to US15/169,617 priority patent/US9693980B2/en
Priority to US15/195,608 priority patent/US9820952B2/en
Priority to US15/195,623 priority patent/US9827215B2/en
Priority to US15/219,245 priority patent/US9789075B2/en
Priority to US15/289,083 priority patent/US20170043016A1/en
Priority to US15/295,933 priority patent/US9795577B2/en
Priority to US15/614,592 priority patent/US10155042B2/en
Priority to US15/684,214 priority patent/US10213381B2/en
Priority to US15/684,197 priority patent/US10363232B2/en
Priority to US15/702,440 priority patent/US10231943B2/en
Priority to US15/794,178 priority patent/US10188619B2/en
Priority to US15/794,197 priority patent/US10154975B2/en
Priority to US15/794,214 priority patent/US10143671B2/en
Priority to US16/012,036 priority patent/US10426748B2/en
Priority to US16/166,272 priority patent/US10596132B2/en
Priority to US16/206,814 priority patent/US10588878B2/en
Priority to US16/206,789 priority patent/US10653778B2/en
Priority to US16/284,221 priority patent/US10835490B2/en
Priority to US16/525,520 priority patent/US10857114B2/en
Priority to US16/573,776 priority patent/US10849869B2/en
Priority to US16/729,363 priority patent/US20200129461A1/en
Priority to US16/818,668 priority patent/US11000493B2/en
Priority to US16/882,663 priority patent/US11154500B2/en
Priority to US16/882,666 priority patent/US11202831B2/en
Priority to US16/882,667 priority patent/US11224659B2/en
Priority to US17/107,724 priority patent/US11660276B2/en
Priority to US17/113,476 priority patent/US11730709B2/en
Priority to US17/146,989 priority patent/US11103472B2/en
Priority to US17/146,950 priority patent/US11065218B2/en
Priority to US17/230,855 priority patent/US11844773B2/en
Priority to US17/378,744 priority patent/US20210338617A1/en
Priority to US17/448,263 priority patent/US11992555B2/en
Priority to US17/540,802 priority patent/US11826428B2/en
Priority to US17/646,241 priority patent/US11918654B2/en
Priority to US18/509,114 priority patent/US20240100002A1/en
Priority to US18/595,716 priority patent/US20240207408A1/en
Priority to US18/641,775 priority patent/US20240277613A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)

Abstract

An oral adjuvant for pharmaceutical immunogen delivery, drug delivery devices comprising the adjuvant and methods of treatment using pharmaceutical formulations comprising the adjuvant (e.g. to treat Th1 cell mediated diseases) are disclosed wherein the adjuvant comprises a lipid and an alcohol arranged to stimulate uptake of the immunogen by dendritic cells and or macrophages. Preferably the adjuvant comprises at least 30% wax, lipid of oil and ethanol, preferably the lipid is linseed oil and preferably the adjuvant further comprises an NSAID such as ibuprofen or a PPAR-gamma agonist. The effects of ibuprofen formulated in 90% linseed oil, 10% ethanol on the survival of influenza challenged mice and a vaginal pessary comprising the ibuprofen formulation intended for administration to prevent premature labour are disclosed.
GBGB1018289.7A 2010-10-29 2010-10-29 Treatment of respiratory disorders Ceased GB201018289D0 (en)

Priority Applications (65)

Application Number Priority Date Filing Date Title
GBGB1018289.7A GB201018289D0 (en) 2010-10-29 2010-10-29 Treatment of respiratory disorders
GB1113728.8A GB2487808A (en) 2010-10-29 2011-08-10 Oral adjuvant or formulation comprising a lipid and an alcohol
PCT/GB2011/052115 WO2012056251A1 (en) 2010-10-29 2011-10-31 Inflammatory disease
EP11784752.5A EP2632431A1 (en) 2010-10-29 2011-10-31 Inflammatory disease
CA2816564A CA2816564A1 (en) 2010-10-29 2011-10-31 Inflammatory disease
AU2011322255A AU2011322255A1 (en) 2010-10-29 2011-10-31 Inflammatory disease
JP2013535515A JP2013544802A (en) 2010-10-29 2011-10-31 Inflammatory disease
BR112013010441A BR112013010441A2 (en) 2010-10-29 2011-10-31 inflammatory disease
CN2011800637601A CN103282021A (en) 2010-10-29 2011-10-31 Inflammatory disease
SG2013033014A SG189551A1 (en) 2010-10-29 2011-10-31 Inflammatory disease
MX2013004817A MX2013004817A (en) 2010-10-29 2011-10-31 INFLAMMATORY DISEASE.
RU2013124514/15A RU2013124514A (en) 2010-10-29 2011-10-31 INFLAMMATORY DISEASE
US13/365,824 US8895536B2 (en) 2010-10-29 2012-02-03 Compositions and methods for treating chronic inflammation and inflammatory diseases
US13/365,828 US8895537B2 (en) 2010-10-29 2012-02-03 Compositions and methods for treating cardiovascular diseases
US14/155,167 US10695432B2 (en) 2010-10-29 2014-01-14 Solid solution compositions and use in severe pain
US14/155,042 US9271950B2 (en) 2010-10-29 2014-01-14 Compositions for treating chronic inflammation and inflammatory diseases
US14/155,080 US9265742B2 (en) 2010-10-29 2014-01-14 Compositions and methods for treating inflammatory pain
US14/155,147 US10695431B2 (en) 2010-10-29 2014-01-14 Solid solution compositions and use in cardiovascular disease
US14/155,108 US9308213B2 (en) 2010-10-29 2014-01-14 Solid solution compositions and use in chronic inflammation
US14/520,141 US9326958B2 (en) 2010-10-29 2014-10-21 Compositions for treating chronic inflammation and inflammatory diseases
US14/520,150 US9381180B2 (en) 2010-10-29 2014-10-21 Compositions and methods for treating chronic inflammation and inflammatory diseases
US14/520,159 US9427422B2 (en) 2010-10-29 2014-10-21 Compositions for treating cardiovascular diseases
US14/821,687 US9744132B2 (en) 2010-10-29 2015-08-07 Solid solution compositions and use in chronic inflammation
US14/975,599 US9504664B2 (en) 2010-10-29 2015-12-18 Compositions and methods for treating severe pain
US14/975,608 US9737500B2 (en) 2010-10-29 2015-12-18 Compositions and methods for treating severe pain
US15/043,327 US9750810B2 (en) 2010-10-29 2016-02-12 Compositions and methods for treating chronic inflammation and inflammatory diseases
US15/061,661 US9775820B2 (en) 2010-10-29 2016-03-04 Solid solution compositions and use in chronic inflammation
US15/169,619 US10004704B2 (en) 2010-10-29 2016-05-31 Compositions and methods for treating chronic inflammation and inflammatory diseases
US15/169,617 US9693980B2 (en) 2010-10-29 2016-05-31 Compositions and methods for treating chronic inflammation and inflammatory diseases
US15/195,608 US9820952B2 (en) 2010-10-29 2016-06-28 Solid solution compositions and use in chronic inflammation
US15/195,623 US9827215B2 (en) 2010-10-29 2016-06-28 Solid solution compositions and use in chronic inflammation
US15/219,245 US9789075B2 (en) 2010-10-29 2016-07-25 Compositions and methods for treating cardiovascular diseases
US15/289,083 US20170043016A1 (en) 2010-10-29 2016-10-07 Solid Solution Compositions and Use in Severe Pain
US15/295,933 US9795577B2 (en) 2010-10-29 2016-10-17 Compositions and methods for treating severe pain
US15/614,592 US10155042B2 (en) 2010-10-29 2017-06-05 Compositions and methods for treating chronic inflammation and inflammatory diseases
US15/684,214 US10213381B2 (en) 2010-10-29 2017-08-23 Solid solution compositions and use in chronic inflammation
US15/684,197 US10363232B2 (en) 2010-10-29 2017-08-23 Compositions and methods for treating severe pain
US15/702,440 US10231943B2 (en) 2010-10-29 2017-09-12 Compositions and methods for treating cardiovascular diseases
US15/794,178 US10188619B2 (en) 2010-10-29 2017-10-26 Solid solution compositions and use in chronic inflammation
US15/794,197 US10154975B2 (en) 2010-10-29 2017-10-26 Solid solution compositions and use in chronic inflammation
US15/794,214 US10143671B2 (en) 2010-10-29 2017-10-26 Solid solution compositions and use in chronic inflammation
US16/012,036 US10426748B2 (en) 2010-10-29 2018-06-19 Compositions and methods for treating chronic inflammation and inflammatory diseases
US16/166,272 US10596132B2 (en) 2010-10-29 2018-10-22 Solid solution compositions and use in chronic inflammation
US16/206,814 US10588878B2 (en) 2010-10-29 2018-11-30 Solid solution compositions and use in chronic inflammation
US16/206,789 US10653778B2 (en) 2010-10-29 2018-11-30 Compositions and methods for treating chronic inflammation and inflammatory diseases
US16/284,221 US10835490B2 (en) 2010-10-29 2019-02-25 Solid solution compositions and use in chronic inflammation
US16/525,520 US10857114B2 (en) 2010-10-29 2019-07-29 Compositions and methods for treating severe pain
US16/573,776 US10849869B2 (en) 2010-10-29 2019-09-17 Compositions and methods for treating chronic inflammation and inflammatory diseases
US16/729,363 US20200129461A1 (en) 2010-10-29 2019-12-28 Compositions Comprising Cancer Drug-Fatty Acid Conjugates
US16/818,668 US11000493B2 (en) 2010-10-29 2020-03-13 Solid solution compositions and use in chronic inflammation
US16/882,663 US11154500B2 (en) 2010-10-29 2020-05-25 Solid solution compositions and use in chronic inflammation
US16/882,666 US11202831B2 (en) 2010-10-29 2020-05-25 Solid solution compositions and use in cardiovascular disease
US16/882,667 US11224659B2 (en) 2010-10-29 2020-05-25 Solid solution compositions and use in severe pain
US17/107,724 US11660276B2 (en) 2010-10-29 2020-11-30 Compositions and methods for treating chronic inflammation and inflammatory diseases
US17/113,476 US11730709B2 (en) 2010-10-29 2020-12-07 Compositions and methods for treating severe pain
US17/146,989 US11103472B2 (en) 2010-10-29 2021-01-12 Oral suspensions comprising a non-steroidal anti-inflammatory drug (NSAID)
US17/146,950 US11065218B2 (en) 2010-10-29 2021-01-12 Compositions and methods for treating chronic inflammation and inflammatory diseases
US17/230,855 US11844773B2 (en) 2010-10-29 2021-04-14 Solid solution compositions and use in chronic inflammation
US17/378,744 US20210338617A1 (en) 2010-10-29 2021-07-18 Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases
US17/448,263 US11992555B2 (en) 2010-10-29 2021-09-21 Solid solution compositions and use in chronic inflammation
US17/540,802 US11826428B2 (en) 2010-10-29 2021-12-02 Solid solution compositions comprising cannabidiols
US17/646,241 US11918654B2 (en) 2010-10-29 2021-12-28 Solid solution compositions and use in severe pain
US18/509,114 US20240100002A1 (en) 2010-10-29 2023-11-14 Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases
US18/595,716 US20240207408A1 (en) 2010-10-29 2024-03-05 Solid Solution Compositions and Use in Severe Pain
US18/641,775 US20240277613A1 (en) 2010-10-29 2024-04-22 Solid Solution Compositions and Use in Chronic Inflammation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1018289.7A GB201018289D0 (en) 2010-10-29 2010-10-29 Treatment of respiratory disorders

Publications (1)

Publication Number Publication Date
GB201018289D0 true GB201018289D0 (en) 2010-12-15

Family

ID=43401508

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1018289.7A Ceased GB201018289D0 (en) 2010-10-29 2010-10-29 Treatment of respiratory disorders
GB1113728.8A Withdrawn GB2487808A (en) 2010-10-29 2011-08-10 Oral adjuvant or formulation comprising a lipid and an alcohol

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1113728.8A Withdrawn GB2487808A (en) 2010-10-29 2011-08-10 Oral adjuvant or formulation comprising a lipid and an alcohol

Country Status (11)

Country Link
EP (1) EP2632431A1 (en)
JP (1) JP2013544802A (en)
CN (1) CN103282021A (en)
AU (1) AU2011322255A1 (en)
BR (1) BR112013010441A2 (en)
CA (1) CA2816564A1 (en)
GB (2) GB201018289D0 (en)
MX (1) MX2013004817A (en)
RU (1) RU2013124514A (en)
SG (1) SG189551A1 (en)
WO (1) WO2012056251A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
RU2635188C2 (en) 2011-02-04 2017-11-09 ИнФёрст Хэлткэр Лимитед Compositions and methods for treatment of chronic inflammation and inflammatory diseases
JP2014040396A (en) * 2012-08-23 2014-03-06 Chemo-Sero-Therapeutic Research Institute Adjuvant composition containing dyslipidemia therapeutic agent
CN104098686B (en) * 2013-04-03 2016-03-23 苏州偲聚生物材料有限公司 Polypeptide, the detection means comprising this polypeptide and detection kit
CN103880941B (en) * 2012-12-21 2016-02-10 苏州偲聚生物材料有限公司 Polypeptide, the detection means comprising this polypeptide and detection kit
CN103880924B (en) * 2012-12-21 2016-03-23 苏州偲聚生物材料有限公司 Polypeptide, the detection means comprising this polypeptide and detection kit
CN104968368B (en) * 2013-01-14 2018-05-04 因佛斯特医疗有限公司 Solid solution compositions and their use in severe pain
CN104098681B (en) * 2013-04-03 2016-08-10 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN104098671A (en) * 2013-04-03 2014-10-15 苏州偲聚生物材料有限公司 Polypeptide, and detection member and detection kit both containing same
CN104098685B (en) * 2013-04-03 2016-03-23 苏州偲聚生物材料有限公司 Polypeptide, the detection means comprising this polypeptide and detection kit
HK1215681A1 (en) * 2013-04-18 2016-09-09 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AU2014309570B2 (en) * 2013-08-19 2017-04-20 Enzychem Lifesciences Corporation Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma
US20160199338A1 (en) * 2013-08-19 2016-07-14 Enzychem Lifesciences Corporation Compositions containing monoacetyldiacylglycerol compound as an active ingredient for preventing or treating rheumatoid arthritis
AU2014311432A1 (en) 2013-08-30 2016-03-03 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN103932977A (en) * 2014-04-15 2014-07-23 江苏正大清江制药有限公司 Preparation method of celecoxib preparation
CN103893171B (en) * 2014-04-19 2016-05-25 武汉胜达康生物科技有限公司 The application of benzydamine hydrochloride in preparation treatment or flu-prevention virus infective medicament
AU2017424129B2 (en) * 2017-07-18 2021-12-09 Deyi Pharmarmaceutical Ltd. Application of cannabidiol in treatment of pulmonary hypertension
CN109419786B (en) * 2017-08-31 2021-04-30 汉义生物科技（北京）有限公司 Application of cannabidiol in preparation of anti-influenza drugs
US11452707B2 (en) * 2017-08-31 2022-09-27 Hanyi Bio-Technology (Beijing) Co., Ltd. Use of cannabidiol in preparation of drugs for resisting against influenza
US12310959B2 (en) 2019-12-09 2025-05-27 Nicoventures Trading Limited Oral compositions with reduced water content
US12439949B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Oral compositions with reduced water activity
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
US12439952B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Moist oral compositions
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US12433321B2 (en) 2019-12-09 2025-10-07 Nicoventures Trading Limited Oral composition with beet material
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
US20230045616A1 (en) * 2019-12-27 2023-02-09 Nonprofit Organization North East Japan Study Group Cancer treatment method and medicine
CN111214467A (en) * 2020-03-05 2020-06-02 南京巴傲得生物科技有限公司 Application of indoprofen in resisting proinflammatory activity of HMGB1
CN111281973A (en) * 2020-03-31 2020-06-16 清华大学 Vaccine adjuvant containing TRPV2 agonist and application thereof
JP2024523520A (en) 2021-06-25 2024-06-28 ニコベンチャーズ トレーディング リミテッド Oral Products and Methods of Manufacturing
KR20230050232A (en) * 2021-10-07 2023-04-14 주식회사 이노보테라퓨틱스 Pharmaceutical composition for inhibiting HSP47 comprising benzofuranyl hydroxyphenyl methanone derivative

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059626A (en) * 1988-07-25 1991-10-22 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
ES2148345T3 (en) * 1993-10-22 2000-10-16 Hexal Ag PHARMACEUTICAL COMPOSITION WITH CYCLOSPORINE A, A DERIVATIVE OF VITAMIN E AND AN EMULSIONANT.
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
US20070036831A1 (en) * 2005-08-09 2007-02-15 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
WO2008070950A1 (en) * 2006-12-13 2008-06-19 Laboratoires Mauves Inc. Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms
CN102341125B (en) * 2008-11-19 2014-02-12 梅里亚有限公司 Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
RU2635188C2 (en) * 2011-02-04 2017-11-09 ИнФёрст Хэлткэр Лимитед Compositions and methods for treatment of chronic inflammation and inflammatory diseases

Also Published As

Publication number Publication date
MX2013004817A (en) 2013-07-03
CA2816564A1 (en) 2012-05-03
SG189551A1 (en) 2013-06-28
AU2011322255A1 (en) 2013-05-23
JP2013544802A (en) 2013-12-19
WO2012056251A1 (en) 2012-05-03
EP2632431A1 (en) 2013-09-04
GB2487808A (en) 2012-08-08
RU2013124514A (en) 2014-12-10
GB201113728D0 (en) 2011-09-21
BR112013010441A2 (en) 2016-08-09
CN103282021A (en) 2013-09-04

Similar Documents

Publication Publication Date Title
GB201018289D0 (en) Treatment of respiratory disorders
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
WO2011139684A3 (en) Nicotine-containing pharmaceutical compositions
WO2008079404A3 (en) Pharmaceutical compositions for treatment of parkinson's disease and related disorders
MX2016010213A (en) Novel pharmaceutical formulations.
NZ598654A (en) Immunogenic compositions including tlr activity modulators
AR075735A1 (en) PHARMACEUTICAL COMPOSITIONS OF IMMEDIATE RELEASE THAT INCLUDE OXYCODONE AND NALOXONE. USE
MX354423B (en) Extended release formulations of rasagiline and uses thereof.
BR112015026418A2 (en) formulation of colchicine prolonged release as an active ingredient, method for treating and / or preventing cardiovascular disease or inflammatory disease in an individual, process of preparing a colchicine prolonged release tablet and molded and compressed prolonged release therapeutic composition comprising colchicine and excipients combined in a matrix
UY32109A (en) METHODS TO USE AMINOPIRIDINE SUSTAINED RELEASE COMPOSITIONS
AR084865A1 (en) FAST DISINTEGRATION PREPARATION, DISPERSABLE COMPRESSED BY ORAL ROUTE
RU2013144383A (en) DOSAGE FORM AND APPLICATION OF DIETHYL STEELBESTROL FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER
AR065580A1 (en) IMPROVEMENTS IN MEDICINAL COMPOSITIONS OR RELATED TO THE SAME
TN2015000135A1 (en) Modified release formulations for oprozomib
TR201821157T4 (en) ORAL APPLICATION SOLID COMPOSITION CONTAINING IBANDRONIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT AND VITAMIN D.
MX2013012206A (en) Method of producing substances with supersaturated gas, transdermal delivery thereof, and uses thereof.
AR065582A1 (en) IMPROVEMENTS IN MEDICINAL COMPOSITIONS OR RELATED TO THE SAME
Lashari et al. The ability of mucoadhesive gingival patch loaded with EGCG on IL-6 and IL-10 expression in periodontitis
MX2023002649A (en) New formulation of gamma-aminobutyric acid.
MX2013012204A (en) Method of producing substances with supersaturated gas,transdermal delivery device thereof, and uses thereof.
AR076479A1 (en) PHARMACEUTICAL COMPOSITIONS FOR MAINTENANCE THERAPIES CONTAINING AS AN ACTIVE INGREDIENT AN ANTIBODY RECOGNIZING THE CLASS I HUMAN LEUCOCITARY ANTIGEN (HLA)
Movassaghian et al. Clinical anesthetic effectiveness of intraoral mucoadhesive tablets of amitriptyline in healthy volunteers
MX2013012205A (en) Method of producing substances with supersaturated gas, transdermal delivery device thereof, and uses thereof.
MX2009003770A (en) Robust sustained release formulations of oxymorphone and methods of use thereof.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)